The United States Patent and Trademark Office (USPTO) has recently granted a patent to Australia-based clinical-stage cell therapy company Chimeric Therapeutics (ASX: CHM) for its CHM 0201 (CORE-NK) technology, which targets blood cancers and solid tumours.
The technology is used in the production of Chimeric’s clinical-stage universal NK cell asset CHM 0201, as well as preclinical-stage NK cell assets CHM 0301, CHM 1301, and CHM 2301.
The allowed patent application 16/614,132, entitled “Compositions for Expanding Natural Killer Cells”, is expected to provide patent protection until 2039.
Chimeric’s CEO and Managing Director Jennifer Chow said, “We are delighted with USPTO’s decision to grant patent protection for our CORE-NK platform in the United States, the single largest global market for biopharmaceutical products. The allowance of this first US patent application lays the foundation for the intellectual property portfolio supporting our best-in-class pipeline of allogeneic NK cell assets.”
Chimeric Therapeutics focuses on the discovery, development, and commercialisation of cell therapies for cancer patients. The Company holds an exclusive worldwide license for the development and commercialisation of the granted patent and associated applications in oncology, immune disorders, and infectious diseases.
The patented CHM 0201 (CORE-NK platform) represents a clinically validated NK cell platform, with data from a comprehensive phase 1A clinical trial demonstrating safety and efficacy in blood cancers and solid tumors, as reported in March 2022. Building upon this promising outcome, two additional Phase 1B clinical trials have been initiated to explore CHM 0201 in combination regimens. Chimeric is also leveraging the CHM 0201 platform to develop new next-generation NK and CAR NK assets.
CHM 0201 (CORE-NK platform) is a clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM 0201 in combination regimens have been initiated. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.
In addition to CHM 0201, Chimeric is advancing other assets in its pipeline. CHM 2101 (CDH17 CAR T), a third-generation CDH17 CAR T therapy originating from the University of Pennsylvania, exhibited compelling preclinical evidence, including complete tumor eradication across seven cancer types. Meanwhile, CHM 1101 (CLTX CAR T) is a novel CAR T therapy under investigation for the treatment of solid tumors, currently undergoing a phase 1B clinical trial.
In H1 FY24, Chimeric Therapeutics reported a profit amounting to $2.4 million, a turnaround from H1 FY23’s loss of $11.7 million. This profit was attributed to introduction fees received during the period and a second overseas finding for the research and development tax incentive, resulting in an additional $3.7 million in revenue. As of December 31, 2023, the Company’s cash reserves stood at $3.5 million.
Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024. Patents like these further cement the Company’s resolve.
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
- Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
- Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
- CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
1 Comment
Shraddha13
Thank you for sharing! To explore further
Replyhttps://www.360iresearch.com/library/intelligence/leukemia-molecular-diagnostics